For decades, treating depression has been a slow and frustrating process.
Most antidepressants target serotonin and take weeks to show effects.
But now, a once-infamous drug is returning in a completely new form.
A nasal spray, chemically similar to ketamine, has entered the scene.
Known as Spravato, it is aimed at patients who have seen no results from traditional antidepressants.
A radically different way to treat depression
Spravato doesn’t focus on serotonin like older drugs. Instead, it targets a neurotransmitter called glutamate, helping to rebuild brain connections.
This can lead to significant relief within hours, says Professor Ian Hickie from the University of Sydney.
Starting Thursday, up to 30,000 Australians will gain access to Spravato through the Pharmaceutical Benefits Scheme.
It marks the first government-funded innovation for depression treatment in three decades.
A hidden cost behind the breakthrough
But while the spray becomes cheaper, it’s not entirely without obstacles. Patients must still cover additional treatment and monitoring costs at certified clinics.
Even more, the spray doesn’t work for everyone. Studies show only about half of treatment-resistant patients see significant improvements.
Despite these challenges, the drug’s approval is seen as a milestone by health authorities and pharmaceutical leaders.
They hope it can finally offer new hope to those left behind by traditional therapies.
This article is based on information from The Guardian.